Cure8 research brief
Patients with hidradenitis suppurativa have higher baseline IBD risk, and IL-17 inhibitors are effective HS treatments. People with Crohn’s disease or ulcerative colitis (or those at risk) may worry whether these drugs increase IBD onset or flares.
Patients with HS considering or receiving IL-17 inhibitors; patients with personal or family history of IBD; gastroenterologists and dermatologists prescribing biologics; researchers studying biologic safety.
This JAMA Dermatology systematic review and meta-analysis pooled randomized trials, nonrandomized studies, and case reports to measure how often inflammatory bowel disease (new-onset or flares of Crohn disease or ulcerative colitis) was reported in patients treated with interleukin-17 inhibitors for hidradenitis suppurativa.
Across 10 RCTs through week 16 there were 6 new-onset IBD events among 2572 patients on IL-17 inhibitors and 0 among 1066 placebo-treated patients; pooled analyses did not show a statistically significant increased risk.
Nonrandomized studies and extensions reported additional cases, and the authors note low event counts and inconsistent reporting as limitations. The review focuses on safety signal evaluation rather than proving causation.
It does not provide new individual patient management advice, but summarizes rates reported in trials and observational studies and highlights uncertainty due to small numbers and variable follow-up.
If you or a clinician are considering an IL-17 inhibitor for HS and have personal or family history of IBD, this report underscores that IBD events were rare in trials but that evidence is limited; discussion with a gastroenterologist may be reasonable for higher-risk patients.
The article is an abstract-level systematic review and meta-analysis published in JAMA Dermatology. The authors emphasize low absolute event counts, short randomized-trial follow-up (typical reporting through week 16), and inconsistent reporting across studies as important limitations.
This brief is grounded in the source abstract; it does not substitute for reading the full paper or individual study reports.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
People with IBD or Crohn's disease considering or taking upadacitinib may worry about rare but serious risks such as heart attacks, strokes, or blood clots. This meta-analysis found no clear increase in those events...
This Taiwanese multicenter real-world study reports high 52-week clinical response and remission rates, sustained one-year drug persistence, and meaningful fistula healing with ustekinumab in patients with Crohn’s...
This analysis summarizes longer-term safety data for upadacitinib (Rinvoq) in people with moderate to severe ulcerative colitis and Crohn’s disease.
